Lexicon Pharmaceuticals, Inc. (LXRX): Price and Financial Metrics
Lexicon Pharmaceuticals, Inc. (LXRX)
Today's Latest Price: $1.94 USD
Updated Jul 2 4:00pm
Add LXRX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
LXRX Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for LXRX is 5.86 -- better than 92.6% of US stocks.
- LXRX's current price/earnings ratio is 2.5, which is higher than merely 2.65% of US stocks with positive earnings.
- As for revenue growth, note that LXRX's revenue has grown 579.52% over the past 12 months; that beats the revenue growth of 98.86% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Lexicon Pharmaceuticals Inc are ALBO, TNAV, MEET, FOLD, and PULM.
- Visit LXRX's SEC page to see the company's official filings. To visit the company's web site, go to www.lexpharma.com.
LXRX Stock Price Chart Technical Analysis Charts
LXRX Price/Volume Stats
| Current price | $1.94 | 52-week high | $6.49 |
| Prev. close | $2.01 | 52-week low | $1.13 |
| Day low | $1.93 | Volume | 547,079 |
| Day high | $2.03 | Avg. volume | 950,355 |
| 50-day MA | $1.97 | Dividend yield | N/A |
| 200-day MA | $2.94 | Market Cap | 207.52M |
Lexicon Pharmaceuticals, Inc. (LXRX) Company Bio
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes and carcinoid syndrome in progress. The company was founded in 1995 and is based in The Woodlands, Texas.
LXRX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $1.94 | $7.85 | 287% |
We started the process of determining a valid price forecast for Lexicon Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Lexicon Pharmaceuticals Inc ranked in the 75th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 288.67% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Lexicon Pharmaceuticals Inc, consider:
- In the past 4.13 years, Lexicon Pharmaceuticals Inc has a compound free cash flow growth rate of -0.1%; that's better than only 10.17% of cash flow producing equities in the Healthcare sector, where it is classified.
- Lexicon Pharmaceuticals Inc's weighted average cost of capital (WACC) is 6%; for context, that number is higher than merely 3.78% of tickers in our DCF set.
- Lexicon Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 279% |
| 1% | 283% |
| 2% | 287% |
| 3% | 291% |
| 4% | 294% |
| 5% | 298% |
Want more companies with a valuation profile/forecast similar to that of Lexicon Pharmaceuticals Inc? See AMEH, MYL, ABC, CVS, and HZNP.
Loading social stream, please wait...